We have studied prospectively, in nine children requiring sedation to facilitate mechanical ventilation, the metabolic, biochemical and haemodynamic effects of infusion of propofol. Children were given infusions of propofol 1-4 mg kg 
As the use of propofol becomes more widespread in adult intensive care units, 1 2 the reported deaths of seven children [3] [4] [5] who received propofol for sedation as part of their intensive care management is of considerable concern. The children aged between 4 weeks and 9 yr who required mechanical ventilation for severe upper respiratory tract infections developed lipaemia and metabolic acidosis before death. Although no casual relationship was established, the Committee on Safety of Medicines issued a serious adverse effects warning leading to the immediate abandonment of propofol as a sedative agent in the paediatric intensive care unit. 6 The aim of this open prospective study was to investigate the effects of a sedative infusion regimen of propofol on the metabolic, biochemical and haemodynamic changes in a group of children without upper respiratory tract infections over a 48-h period. Propofol was used in combination with fentanyl at low doses and under very specific conditions to facilitate ventilation in a group of children in a cardiac surgical intensive care unit for a predetermined period.
Patients and methods
This study was approved by the Ethics Committee of the Royal Liverpool Children's NHS Trust. Parents were fully informed of the current concerns about the use of propofol in children. They were also made aware of the case report of the five deaths and given an information sheet describing these issues in simple terms. An Exemption from Licences of the Medicine Special Cases and Miscellaneous Provisions Order 1972 was also obtained from the Medicines Control Agency.
Nine child needing sedation to facilitate mechanical ventilation after cardiac surgery or weaning from ventilation were considered eligible for the study. Mean arterial pressure was monitored invasively via an indwelling arterial cannula in all children, and in five children central venous pressure was monitored. Concurrent sedatives were stopped and infusions of propofol 1-4 mg kg 91 h 91 and fentanyl 1-5 g kg 91 h 91 were commenced without loading boluses. Neuromuscular blocking agents were not given. Sedation was scored every 4 h. 7 Bolus doses of propofol and fentanyl, equivalent to 25% of the current hourly infusion rate, were given during interventions such as tracheal suctioning or physiotherapy. Propofol was continued for 48 h or until the child was considered ready for tracheal extubation, if sooner. The lungs were ventilated to mild hypocapnia with oxygen-enriched air and inotropic support was continued according to clinical requirements. Heart rate, arterial pressure, central venous pressure, fluid input and urine output were recorded hourly. Parenteral nutrition containing Intralipid was avoided. In addition to hourly cardiovascular and respiratory observations made in the ICU, 6-hourly arterial blood-gas analysis and 12-hourly measurements of serum concentrations of electrolytes, urea, creatinine, glucose, lactate, triglycerides, total bilirubin, ␥-glutamyltransferase (GGT), aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase were made (Axon Clinical Chemistry Analyser, Bayer Diagnostics, UK). 8 Age specific normal ranges generated within our laboratory were used for comparisons. Urine was collected 12-hourly and analysed for ketones and organic acids.
Statistical analysis was performed using the Kruskal-Wallis non-parametric ANOVA test. All values are expressed as mean (95% confidence interval (CI)). P:0.05 was considered statistically significant.
Results
Nine children (four males) completed the study. One child required a second episode of ventilation, 2 months later, after developing left upper lobe pulmonary consolidation resulting in 10 episodes of propofol infusion. Median age was 19 months (95% CI 2.2-104.7 months) and mean weight 13.9 (2.8-25.0) kg. The trachea of one child was extubated within 24 h and in two children, propofol infusion was continued for clinical reasons for 84 h and 144 h with no adverse effects. Five children with Down's syndrome had atrioventricular septal defect (AVSD) repair, three had complete repair of tetralogy of Fallot and one had a tracheal stent insertion for tracheomalacia. The mean dose of propofol infusion was 2.1 (1. . No gross lipaemia was observed on direct visual inspection in any of the blood samples obtained. Although serum triglyceride concentrations were increased above the normal range quoted for our laboratory at 12 h, 24 h and 36 h, there were Table 1 Metabolic and biochemical changes during the 48-h infusion of propofol (mean (95% confidence interval)). There were no significant differences in any variable at any time during the study. (Nine children were studied but one child was sedated twice, separated by a period of 2 months, making 10 clinical episodes) 
Discussion
Adequate sedation and analgesia is an integral part of intensive care management. Infusions of midazolam, propofol, fentanyl and alfentanil are used commonly in adult intensive care. However, the last available survey in 1991 of PICU in the UK revealed that at that time the majority were using these sedatives outside their product licenses. 9 The pharmacodynamics and pharmacokinetics of propofol make it ideal for maintenance of prolonged sedation of patients undergoing mechanical ventilation in the ICU. Propofol has been studied extensively in adult intensive care, where it has been shown to provide satisfactory sedation and rapid recovery with minimal side effects. [10] [11] [12] [13] In contrast, there is little published information on the clinical use of propofol in critically ill children. 14 15 The case report of five deaths in children with upper respiratory tract infections described propofol infusions at concentrations varying from 4 mg kg 91 h 91 to a short maximum rate of 13.6 mg kg 91 h 91 for 8 h. 3 Even for this relatively short period, the equivalent infusion rate for a 70-kg adult would be 95.2 ml h 91 giving a total volume of 762 ml in the 8-h period. The doses used in our study (mean 2.1 mg kg 91 h
91
) were much lower and equivalent to approximately 15 ml h 91 for a 70-kg adult, which is a more generally acceptable rate of infusion used in adult intensive care. Parke and colleagues 3 acknowledge that propofol contains 0.1 g of lipid per millilitre and that 10% Intralipid from the propofol infusion might have contributed to the deaths. They calculated that even at the maximum rates of propofol infusion used, less than half of the recommended infusion rate of 10% Intralipid in infants was given (Intralipid data sheet, Pharmacia, Milton Keynes, UK) and therefore the lipid content of propofol was unlikely to be the sole cause of the deaths. However, it is not clear if the five infants also had supplementary parenteral nutrition and how much Intralipid was prescribed in addition to that received from the propofol infusion. As lipid metabolism may be impaired in children with sepsis, the authors were correct in observing that added lipid load from propofol may have contributed to the lipaemic serum noted. They were also correct to point out that infusions of lipid should be minimized and triglyceride concentrations monitored carefully in septic children.
Several other case reports suggest that there may be a syndrome of propofol associated metabolic acidosis (PAMA) which is idiosyncratic in incidence. The syndrome appears to include metabolic acidosis, hypercapnia and hyperthermia, resulting in hypotension unresponsive to vasopressors and broad complex bradycardia unresponsive to chronotropes or mechanical pacing. 5 This has led some to speculate that this syndrome is similar to that of malignant hyperthermia. 16 The picture of a previously healthy child admitted with a trivial URTI or minor neurological symptoms who suddenly and unexpectedly dies after administration of a specific agent has led others to draw similarities with the discovery of aspirin producing Reye's syndrome in children. Unfortunately, there are no data available in terms of number of patient days over which propofol was infused to allow an estimate of the incidence of PAMA and there are still many unanswered questions. If PAMA is an idiosyncratic response why is it seen only in children receiving infusions and not in those who receive propofol for induction of anaesthesia? All the reports of PAMA are in infants and young children; is this a maturational problem in relation to lipid load? Why is PAMA not seen in adults receiving infusion of propofol; is it being missed because deaths from cardiac arrhythmias are more explicable in an adult population?
In 1992 the United States Food and Drugs Authority advisory committee (Anesthetic and Life Support Drugs) concluded that propofol has no direct link to paediatric deaths in hospital intensive care units and no identifiable link to adverse cardiac events in children and adults 17 . A recent study in 28 children has defined the pharmacokinetics of propofol and recommended a dose regimen to maintain optimal sedation which requires a serum concentrations of 1 mg litre
. The regimen varies with time, starting at infusion rates of 7.5 mg kg 91 h 91 and decreasing to 4.3 mg kg 91 h 91 over 4 h. 18 We recommend a much lower dose of 2.1 mg kg 91 h
. This difference in dose rates probably results from our concomitant use of an opioid, which contributed to lower propofol requirements. When used under the specifically controlled circumstances such as those we have described in appropriately monitored and resuscitated children, we believe that propofol sedation has a valuable role in paediatric intensive care. In our practice we have found propofol to be particularly useful in allowing rapid changes in sedation levels and so facilitating ventilation and weaning. Although we have studied only a small number of children we could find no evidence of progressive acidosis or significant metabolic or biochemical derangements.
We have demonstrated that in this small group of children without respiratory disease and not receiving parenteral nutrition, sedation with propofol caused no significant haemodynamic, metabolic or biochemical changes. In no instance did the infusion rate have to be reduced from that dictated by the study design because of adverse haemodynamic effects. No significant changes in blood lactate concentrations occurred, indicating adequate tissue oxygenation. Our findings support those of a similar study in 10 critically ill adults receiving propofol infusions (2-4 mg kg 91 h
). No significant changes in global oxygen transport and delivery, lactate concentration and cardiac output were noted, and there was no evidence of lipaemia or triglyceridaemia, 13 although the adult liver may be better able to handle lipids in sepsis.
We conclude that propofol may be used in postoperative cardiac patients in the doses recommended and in combination with an opioid. We found that propofol was useful in sedating children with Down's syndrome who are often confused on emerging from sedation. We agree with those who request correctly conducted clinical studies to reevaluate the use of propofol infusions in children. 15 However, despite enthusiasts such as Reed and Blumer declaring, "propofol bashing: the time to stop is now" 19 we still have several reservations about its indiscriminate use in sick children. We recommend that until more information is available on the incidence of PAMA and its precipitating factors, propofol should not be administered to children who are suffering from an acute infective process, particularly an upper respiratory tract infection; it should not be used as the sole sedative agent; it should not be infused at greater than 5 mg kg 91 h
; and its continued use should be reviewed daily.
